** Leerink Partners lowers PT on drugmaker Regeneron Pharmaceuticals REGN.O to $762 from $880; maintains rating of "market perform"
** Brokerage says it lowered 2025 EPS estimates to $40.96 from $44.01 due to REGN's eye drug Eylea franchise pressures and investment spending requirements; analysts on average estimate 2025 EPS to be $44.76, according to data compiled by LSEG
** Leerink notes REGN may face potential pricing pressure on Eylea HD in international markets outside of U.S.
** Last year, REGN reported Q3 sales of $392 mln for higher dose version of Eylea, missing expectations of $417 mln
** Brokerage says it expects REGN to defend its Eylea 2mg market share against Amgen's AMGN.O biosimilar, Pavblu
** Expects U.S. Eylea sales to be constrained due to lack of pre-filled syringe, monthly dosing and RVO indication
** REGN fell 21.3% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。